<DOC>
	<DOCNO>NCT02030444</DOCNO>
	<brief_summary>The overall aim study compare standard stag lung cancer ( include clinical examination , CT , MRI , bone scan PET-CT ) comprehensive stag - include new stag method ( PET-MRI systematic mapping mediastinal hilar lymph node use endobronchial ultrasound ) respect disease stage outcomes therapy .</brief_summary>
	<brief_title>Extensive Staging Lung Cancer</brief_title>
	<detailed_description>The trial randomize , explorative study . Patients undergoing examination suspicion lung cancer ( Stage I-III ) randomize either standard diagnostic work-up lung cancer ( Arm A , n=75 ) comprehensive diagnostic work-up ( Arm B , n=75 ) standard examination plus endobronchial-screening metastatic lymph node ( EBUS-TBNA ) PET-MRI . All patient undergo today ' standard examination diagnose stag lung cancer . This individualized patient accord current guideline . In addition standard diagnostic work-up , patient interventional group ( ArmB ) undergo 1 ) PET-MRI 2 ) systematic mediastinal hilar lymph node map use EBUS-TBNA ( endobronchial ultrasound transbronchial needle aspiration lymph node ) 1 . PET-MRI PET-MRI do immediate standard PET-CT use infusion tracer ( 18-fluorodeoxyglucose , FDG ) . The sequence protocol use MRI standardize study , accord body compartment . Measurement Standard Uptake Values ( SUV ) tracer ( FDG ) record pathological lesion . In mediastinum , lymph node station evaluate description visible node . 2 . Systematic mediastinal map The EBUS-TBNA do initial bronchoscopy use standard conscious sedation accord local guideline St.Olavs Hospital . Each lymph node station ( station 2 , 4 , 7 , 10 11 bilateral ) examine lymph node ≥ 0,5 cm short diameter easily accessible punctured rapid on-site cytological evaluation ( ROSE ) . After initial diagnostic work-up complete , patient give treatment accord exist guideline lung cancer base give clinical stage . For patient undergo surgery accessible lymph node resect accord standard practice . Every resect lymph node carefully name accord standard lymph station comparison clinical finding .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>1 . Patients undergoing examination suspicion lung cancer ( SCLC NSCLC ) St. Olavs Hospital 2 . Potentially curable disease referral time ( Stage IIII , base first CT ) 3 . Age ≥ 18 year 4 . ECOG Performance 02 5 . No serious concomitant disorder ( example mark reduced respiratory capacity , active infection , unstable cardiovascular disease , renal dysfunction ) opinion investigator would compromise patient 's ability complete study interfere evaluation efficacy safety study procedure 6 . No contraindication study specific procedure bronchoscopy , CT , MRI PET . 7 . No condition medical , social , psychological could prevent adequate information followup 8 . No pregnancy lactate woman 9 . Written inform consent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Neoplasms Staging</keyword>
	<keyword>Bronchoscopy</keyword>
	<keyword>Nuclear Medicine</keyword>
	<keyword>Radiology</keyword>
</DOC>